Biotech bil­lion­aire Di­et­mar Hopp digs deep­er to back one of the drug de­vel­op­ers in his port­fo­lio

Biotech bil­lion­aire Di­et­mar Hopp is open­ing up the cash vault to help out one of his biotech star­tups.

Op­er­at­ing through dievi­ni Hopp BioTech hold­ing, Hopp has sunk a lit­tle more than $40 mil­lion in­to Hei­del­berg Phar­ma. The mon­ey can be put to use on the Phase I/II clin­i­cal pro­gram for their lead drug: HDP-101, a BC­MA AT­AC for mul­ti­ple myelo­ma. HDP-102, a CD37 AT­AC for non-Hodgkin’s lym­phoma, and HDP-103, a PS­MA AT­AC for metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer, are in pre­clin­i­cal test­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER